Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 19(11), P. 1479 - 1481
Published: Nov. 1, 2024
Language: Английский
Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)
Published: March 1, 2025
Abstract Circulating tumour DNA (ctDNA) represents an increasingly important biomarker for the screening, diagnosis and management of patients in clinical practice advanced/metastatic disease across multiple cancer types. In this context, ctDNA-based comprehensive genomic profiling is now available patient decisions, several companion diagnostic assays have been approved by regulatory agencies. However, although assessment ctDNA levels Phase II-III drug development gathering momentum, it remains somewhat surprisingly limited early I phases light potential opportunities provided such analysis. perspective review, we investigate hurdles applying testing inclusion monitoring phase 1 trials. This will enable more informed decisions regarding inclusion, dose optimization, proof-of-mechanism biological activity molecular response, thereby supporting evolving oncology paradigm. Furthermore, highlight use cost-efficient, agnostic genome-wide techniques (such as low-pass whole genome sequencing fragmentomics) methylation-based methods to facilitate a systematic integration trial settings.
Language: Английский
Citations
1
MedComm, Journal Year: 2024, Volume and Issue: 5(11)
Published: Nov. 1, 2024
Abstract Circulating tumor DNA (ctDNA) methylation, an innovative liquid biopsy biomarker, has emerged as a promising tool in early cancer diagnosis, monitoring, and prognosis prediction. As noninvasive approach, overcomes the limitations of traditional tissue biopsy. Among various biomarkers, ctDNA methylation garnered significant attention due to its high specificity detection capability across diverse types. Despite immense potential, clinical application faces substantial challenges pertaining sensitivity, specificity, standardization. In this review, we begin by introducing basic biology common techniques methylation. We then explore recent advancements faced biopsies. This includes progress screening identification molecular subtypes, monitoring recurrence minimal residual disease (MRD), prediction treatment response prognosis, assessment burden, determination origin. Finally, discuss future perspectives applications. comprehensive overview underscores vital role enhancing diagnostic accuracy, personalizing treatments, effectively progression, providing valuable insights for research practice.
Language: Английский
Citations
7
Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 19(11), P. 1512 - 1524
Published: July 9, 2024
Language: Английский
Citations
6
JCO Precision Oncology, Journal Year: 2024, Volume and Issue: 8
Published: Aug. 29, 2024
Indolent prostate cancer (PCa) is prevalent in the intended use population (adults age 50-79 years) for blood-based multicancer early detection (MCED) tests. We examined detectability of PCa by a clinically validated, targeted methylation-based MCED test.
Language: Английский
Citations
4
medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 15, 2025
Characterization of tumor epigenetic aberrations is integral to understanding the mechanisms tumorigenesis and provide diagnostic, prognostic, predictive information high clinical relevance. Among different tumor-associated signatures, 5 methyl-cytosine (5mC) 5-hydroxymethylcytosine (5hmC) are two most well-characterized DNA methylation alterations linked cancer pathogenesis. 5hmC has a tissue-specific distribution its abundance subjected changes in DNA, making it promising biomarker. Detecting tumor-related tissues highly invasive, while analysis cell-free (cfDNA) poised supplement, if not replace, surgical biopsies. Despite many studies attempted identify new targets for liquid biopsy assays, little known about regulatory roles 5hmC, impacts on molecular phenotypes tumors. Most importantly, whether oncogenic-associated signatures found can be recapitulated patients' cfDNA. In this study, we performed unbiased simultaneous detection 5mC whole-genome modifications at base-resolution from distinct cohorts, patients with bladder or B-Cell lymphoma, their corresponding normal tissues, cfDNAs plasma. We analyzed patters searched gene coding regions cancerous states. then looked cfDNA determine they were consistent tumor-specific patterns. determined functional significance tissue specific transcription uncovered hundreds signatures. These changes, particularly genes enhancers, functionally significant pathways correlated expression. To investigate faithful surrogate devised targeted capture strategy examine lymphoma sufficient sensitivity specificity confirmed that patterns observed tissues. Our results analytic validation as cancer-specific The methods described here systematic characterization elements open avenues discover markers non-invasive diagnosis, monitoring, stratifying cancer.
Language: Английский
Citations
0
Modern Pathology, Journal Year: 2025, Volume and Issue: unknown, P. 100744 - 100744
Published: Feb. 1, 2025
Language: Английский
Citations
0
Diagnostics, Journal Year: 2025, Volume and Issue: 15(7), P. 904 - 904
Published: April 1, 2025
Background: Circulating tumor DNA (ctDNA) may be released from neoplastic cells into biological fluids through apoptosis, necrosis, or active release. In patients with non-small-cell lung cancer (NSCLC), ctDNA analysis is being introduced in clinical practice only for advanced disease management. Nevertheless, an interesting and promising field of application the management early stage cancer, both evaluation before treatment, such as diagnosis screening, prediction histology pathological features. Methods: A thorough review literature published between 2000 2024 was performed on PubMed, utilizing search feature to narrow down titles abstracts containing following keywords: ctDNA, stage, NSCLC. total 20 studies that met all inclusion criteria were chosen this review. Results: review, we summarize increasing evidence suggesting has potential applications levels cancers are very low, posing many technical challenges improving detection rate sensitivity, especially practice, if it implemented detection. Presently, main limitation experimental studies, settings, lack definitive standardization consensus regarding methodology, absence systematically validated analyses, adoption sensitive approaches. Conclusions: Possible analyte open up new fields diagnosis, follow up, which less invasive more precise than other approaches currently use, NSCLC patients.
Language: Английский
Citations
0
Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown
Published: April 1, 2024
Abstract We assessed pre-surgical diagnostic circulating tumor DNA (ctDNA) status in 895 patients with EGFR / ALK -wild-type, clinical stage I–II non-small-cell lung cancer using a tumor-naïve methylation-based cell-free assay. Pre-surgical ctDNA detection was observed 55/414 (13%) I adenocarcinoma (LUAD) and associated poor recurrence-free survival (RFS) (2-year RFS 69% versus 91%; log-rank P < 0.001), approaching that of II LUAD. not prognostic LUAD or non-LUAD. Within LUAD, volume interacted positron emission tomography avidity to predict detection, correlated high-grade pathological features, programmed death ligand-1 (PD-L1) positivity, upstaging. Our findings support positivity as an adverse feature specifically This validated observation assay will enable perioperative trial advances targeted toward high-risk disease.
Language: Английский
Citations
0
Medical Oncology, Journal Year: 2024, Volume and Issue: 41(5)
Published: April 20, 2024
Language: Английский
Citations
0
Journal of Thoracic Oncology, Journal Year: 2024, Volume and Issue: 19(11), P. 1479 - 1481
Published: Nov. 1, 2024
Language: Английский
Citations
0